129 - Time-Synchronized Immune-Guided Partial Tumor Irradiation: Proof-of-Principle Trial (NCT04168320)

166 - Combination of Radiotherapy and Nivolumab for Previously Treated Advanced Gastric Cancer (CIRCUIT Trial): 3-Years Update

246 - Exploratory Analysis of ctDNA and Imaging Response in the Phase I/II CHORUS Study of Canakinumab with Chemoradiation and Durvalumab Consolidation for Stage III NSCLC

2960 - Stereotactic Ablative Radiotherapy Combined with Fruquintinib and Tislelizumab in Metastatic Colorectal Cancer: Updated Findings from a Single-Arm, Prospective Phase II Trial (RIFLE)

2973 - mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible

3110 - Neoadjuvant Chemoradiotherapy plus Sequential Tislelizumab Followed by Surgery for Esophageal Carcinoma (CRISEC study): A Prospective, Single-Arm, Phase II Trial

3170 - Early Results from a Prospective Trial Testing Stereotactic Salvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy-STARR(NCT05455736)

3250 - Phase 2 Prospective Trial of Re-Treatment with 177lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration Resistant Prostate Cancer (RE-LuPSMA): Study Protocol

328 - Cellular Immune and Genomic Biomarkers in NRG-HN003, a Phase I Study Adding Pembrolizumab to Adjuvant Cisplatin and Radiation Therapy (CRT) in Pathologically High-Risk Head and Neck Cancer (HNSCC)